Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) for Treatment of Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Phase II Study

NCT05970627 is registered in ClinicalTrials.gov with Yu jiren as lead sponsor.

NCT NCT05970627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05970627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) for Treatment of Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Phase II Study
Lead sponsor
Yu jiren
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 28, 2023
Completion date
July 28, 2029
Enrollment
30 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of esophagogastric junction, adenocarcinoma of the stomach, epstein-barr virus-associated gastric carcinoma